SLC5A2 and type 2 diabetes mellitus: The uptake of these GDMT may change with the recent updates to consensus guidance that now recommend an SGLT2 inhibitor or GLP1-RA as first or second-line treatment in patients with either high-risk T2D or cardiorenal diseases [23,24,34,46].